Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is set to launch a pivotal Phase 3 clinical study titled ‘A ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Discover a study revealing how flare patterns can predict future atopic dermatitis severity and impact quality of life.

In terms of drug class, immunosuppressants hold the largest market share, accounting for 42.10% in 2024. Their effectiveness ...

While a large body of research has linked eczema to mental health concerns like depression and anxiety — according to the ...

Total product revenues for Q2 were $1.06 billion, an increase of 17% year-over-year. Jakafi net product revenue was $764 million, up 8% year-over-year, and Opzelura revenue reached $164 million, a 35% ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Galderma is a pure-play dermatology company, with a leadership position in the self-care segment of the market, with more than 90% of total sales paid by consumers out of pocket. Its long-term revenue ...

Patients with AD treated with JAK inhibitors show higher risks for PE and deep vein thrombosis than those treated with ...

Nektar Therapeutics (NASDAQ:NKTR) is one of the Stocks With Huge Catalysts on the Horizon. On June 24, Nektar Therapeutics ...